Quest Diagnostics Q3 2026 Revenue Rises to $3.1B, Diluted EPS Up to $2.78
Quest Diagnostics reported Q3 2026 revenue of $3.1B, up 10% YoY, with diluted EPS rising to $2.78. Operating income increased to $479M. Year-to-date revenue reached $9.035B, with net income attributable to Quest at $884M. The company maintained strong cash flow and returned capital through buybacks and dividends, but noted rising operating costs and debt.
How this was made
The 30-second read
Why it matters
The earnings beat and increased dividend suggest short‑term upside, while rising costs and debt warrant caution.
Market read
First‑report earnings data for a mid‑cap health‑care company; relevant for earnings‑driven traders.
What to watch
Accounts receivable increase may signal slower cash conversion; watch for future cash flow trends.
Background
Quest Diagnostics (DGX) filed its Form 10‑Q for Q3 2026, revealing financial results and capital‑return actions.
Ticker impact
Quest Diagnostics reported Q3 2026 revenue of $3.097B and EPS of $2.78, up 29% YoY, marking a fresh earnings disclosure.
likely modest upside as the market prices in the earnings beat and higher dividend payout.
Revenue and EPS both rose double‑digits year‑over‑year, cash balance more than doubled, and dividend/share buyback continued, supporting a bullish bias.
Market effects
Healthcare diagnostics sector may see a lift as a leading player shows robust growth.
U.S. markets could see a slight positive bias in the health‑care segment.
Limited to investors tracking U.S. diagnostic services; no broader macro impact.
Counterpoint
Higher operating costs and rising debt could pressure margins if growth slows.
Key entities
- companyQuest Diagnostics Inc.
U.S. provider of diagnostic testing services.
